医药魔方 / 最新资讯 / 正文

AbbVie与Teneobio签署双特异性抗体TNB-383B全球战略合作,开发多发性骨髓瘤新疗法

医药魔方 医药魔方 来源:医药魔方
2019-02-12
双特异性抗体
原文

2月11日,AbbVie与Teneobio及其子公司TeneoOne联合宣布,双方签订了关于双特异性抗体TNB-383B的全球开发战略合作。


TNB-383B靶向BCMA(B细胞成熟抗原)和CD3的双特异性抗体,通过激活人体免疫系统杀伤BCMA表达阳性的肿瘤细胞。


Teneobio计划在2019上半年启动TNB-383B的人体临床试验。


根据协议,AbbVie将向TeneoOne支付9000万美元预付款,由Teneobio负责TNB-383B的I期开发。AbbVie拥有收购TeneoOne以及主导TNB-383B后续全球开发及商业化的独家选择权利。如果AbbVie选择收购TeneoOne,后者的原股东们将会获得基于注册和商业销售额的里程金。


多发性骨髓瘤是全球最常见的血液肿瘤类型,BCMA是目前比较热门的多发性骨髓瘤靶点之一。AbbVie此前凭借收购伊布替尼在血液肿瘤领域站稳了脚跟。


机器翻译

On February 11, AbbVie and Teneobio and their subsidiary, TeneoOne, announced a global development strategy for the bispecific antibody TNB-383B.

TNB-383B bispecific antibody targeting BCMA (B cell maturation antigen) and CD3 kills BCMA-positive tumor cells by activating the human immune system.

Teneobio plans to launch a human clinical trial of TNB-383B in the first half of 2019.

Under the agreement, AbbVie will pay an advance of $90 million to TeneoOne, and Teneobio will be responsible for the Phase I development of TNB-383B.AbbVie has the exclusive option to acquire TeneoOne and lead the subsequent global development and commercialization of TNB-383B.If AbbVie chooses to buy TeneoOne, its former shareholders will receive mileage based on registration and commercial sales.

Multiple myeloma is the most common type of hematologic cancer in the world.AbbVie had previously gained a foothold in the field of hematology and oncology with the acquisition of ibrutinib.

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号